Clinical trial
A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France
NCT05164055 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- July 11, 2022
- Completion date
- June 30, 2027
- Enrollment
- 17 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.